AABB shapes legislative and regulatory policies that support safety and innovation. The Association engages policymakers, providers, suppliers, manufacturers and patient groups to promote patient and donor care and safety in transfusion medicine and cellular therapies.

Policy Priorities

1. Promote enhanced patient and donor care and safety by supporting innovation and the appropriate regulation and timely introduction of new products and safety technologies for transfusion medicine and biotherapies.
2. Encourage the revision of regulations and guidances that: (1) are duplicative, outdated, unnecessary or overly burdensome; (2) unnecessarily restrict access to products and technologies; and (3) stifle innovation.
3. Oppose unnecessary regulatory burdens, including FDA's onerous final rule regulating laboratory developed tests as medical devices, which will slow innovation and decrease the ability of patients to get appropriate laboratory testing.
4. Advance standards and accreditation worldwide.
5. Support the use of evidence-based policymaking, which includes but is not limited to risk assessment.
6. Support patient blood management as an evidence-based, multidisciplinary approach to improving patient outcomes, potentially safeguarding the nation's blood supply and reducing health care costs.

Activities

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013